FDA WARNS AGAINST COMPOUNDING LYME DRUG

SEPTEMBER 01, 2006

The FDA has called on pharmacists to stop compounding a treatment for Lyme disease that has been linked to at least one patient death and a number of suspected illnesses. The drug, called bismacine or chromocine, is mixed individually by pharmacists for use by injection to treat the symptoms of the tick-borne bacterial disease. According to the FDA, the substance contains high amounts of the heavy metal bismuth and is unapproved for use by humans. Agency officials said that the substance is sometimes prescribed by "alternative health doctors."



SHARE THIS SHARE THIS
0
 

Conference Coverage

Check back here regularly for live conference coverage from the American Academy of Pain Medicine and the upcoming American Pharmacists Association Meeting and Expo. 


 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.